336 related articles for article (PubMed ID: 10344917)
1. Cost effectiveness of pramipexole in Parkinson's disease in the US.
Hoerger TJ; Bala MV; Rowland C; Greer M; Chrischilles EA; Holloway RG
Pharmacoeconomics; 1998 Nov; 14(5):541-57. PubMed ID: 10344917
[TBL] [Abstract][Full Text] [Related]
2. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
Noyes K; Dick AW; Holloway RG;
Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.
Haycox A; Armand C; Murteira S; Cochran J; François C
Drugs Aging; 2009; 26(9):791-801. PubMed ID: 19728752
[TBL] [Abstract][Full Text] [Related]
4. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.
Noyes K; Dick AW; Holloway RG;
Med Decis Making; 2004; 24(5):472-85. PubMed ID: 15358996
[TBL] [Abstract][Full Text] [Related]
5. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
Dooley M; Markham A
Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
[TBL] [Abstract][Full Text] [Related]
6. Pramipexole in the treatment of Parkinson's disease: new developments.
Möller JC; Oertel WH
Expert Rev Neurother; 2005 Sep; 5(5):581-6. PubMed ID: 16162081
[TBL] [Abstract][Full Text] [Related]
7. The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation.
Noyes K; Dick AW; Holloway RG
Med Decis Making; 2007; 27(3):327-34. PubMed ID: 17502449
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.
Palmer CS; Nuijten MJ; Schmier JK; Subedi P; Snyder EH
Pharmacoeconomics; 2002; 20(9):617-28. PubMed ID: 12141889
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
JAMA; 1997 Jul; 278(2):125-30. PubMed ID: 9214527
[TBL] [Abstract][Full Text] [Related]
10. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.
Guttman M
Neurology; 1997 Oct; 49(4):1060-5. PubMed ID: 9339690
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
[TBL] [Abstract][Full Text] [Related]
12. Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life.
Noyes K; Dick AW; Holloway RG;
Value Health; 2006; 9(1):28-38. PubMed ID: 16441522
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of subthalmic nucleus deep brain stimulation for the treatment of advanced Parkinson disease in Hong Kong: a prospective study.
Zhu XL; Chan DT; Lau CK; Poon WS; Mok VC; Chan AY; Wong LK; Yeung JH; Leung MC; Tang VY; Wong RK; Yeung C
World Neurosurg; 2014 Dec; 82(6):987-93. PubMed ID: 25175275
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group.
Clin Neuropharmacol; 2000; 23(1):34-44. PubMed ID: 10682229
[TBL] [Abstract][Full Text] [Related]
15. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
[TBL] [Abstract][Full Text] [Related]
18. Pramipexole extended release: in Parkinson's disease.
Chwieduk CM; Curran MP
CNS Drugs; 2010 Apr; 24(4):327-36. PubMed ID: 20297857
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group.
Shannon KM; Bennett JP; Friedman JH
Neurology; 1997 Sep; 49(3):724-8. PubMed ID: 9305331
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial.
Möller JC; Oertel WH; Köster J; Pezzoli G; Provinciali L
Mov Disord; 2005 May; 20(5):602-10. PubMed ID: 15726540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]